Lead Product(s): CHK-336
Therapeutic Area: Genetic Disease Product Name: CHK-336
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
CHK-336, is a first-in-class, liver-targeted oral small molecule LDHA inhibitor for the treatment of PH. CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021.